Omeros (OMER) Price & Analysis

Compare

705 Followers

OMER Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.95 - $13.60

Previous CloseN/A

Volume193.12K

Average Volume (3M)1.36M

Market Cap

$284.47M

Enterprise Value$529.02M

Total Cash (Recent Filing)$28.74M

Total Debt (Recent Filing)$184.33M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Nov 05, 2025

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding68,055,824

10 Day Avg. Volume816,477

30 Day Avg. Volume1,364,489

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.86

Enterprise Value/Revenue1.28K

Enterprise Value/Gross Profit-728.68

Enterprise Value/Ebitda-4.18

Forecast

1Y Price Target

$9.00

Price Target Upside115.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical PerformanceNarsoplimab demonstrates a differentiated clinical profile and reinforces its potential to become the first approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA).

Financial ProspectsNarsoplimab has the potential to be cash flow positive relatively quickly thus allowing OMER to begin to reinvest in these paused programs.

Bears Say

Financial ChallengesThere is an urgent financial overhang that the company needs to address, indicating financial instability.

Regulatory ConcernsThere is skepticism about FDA approval of narsoplimab due to the limited clinical dataset and lack of new clinical data.

Omeros News

Omeros announces publication of narsoplimab survival outcomes in TA-TMA

Omeros (OMER) announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes...

4d ago

OMER

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Recursion Pharmaceuticals (RXRX) 41.81%...

22d ago

ETH

KGC

Closing Bell Movers: UnitedHealth jumps 10% as Berkshire, Appaloosa buy weakness

In the opening hour of the evening session, U.S. equity futures are mixed: S&P 500 is flat, Nasdaq...

23d ago

NUE

UNH

Omeros reports Q2 EPS (44c), consensus (55c)

The company states: “The reduction in net loss from the prior year quarter was primarily related to narsoplimab...

23d ago

OMER

Promising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy Rating

Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Omeros, retaining the price target of $9.00....

3d ago

OMER

Omeros Corporation’s Positive Earnings Call Highlights Progress

Omeros Corporation (($OMER)) has held its Q2 earnings call. Read on for the main highlights of the call....

5d ago

OMER

Omeros’s Strategic Advancements with Narsoplimab: A Buy Rating Amidst Promising FDA and EMA Reviews

Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Omeros and keeping the price target at...

22d ago

OMER

Omeros Corporation Reports Q2 2025 Financial Results

Omeros Corporation ( ($OMER) ) has released its Q2 earnings. Here is a breakdown of the information Omeros...

22d ago

OMER

H.C. Wainwright says study could be tailwind to uptake of Omeros’ narsoplimab

H.C. Wainwright notes that on July 30 the American Journal of Hematology published results of a single-center, retrospective...

1M ago

OMER

Potential Market Surge for Omeros Driven by Narsoplimab’s Edge Over Eculizumab

Brandon Folkes, an analyst from H.C. Wainwright, maintained the Buy rating on Omeros. The associated price target remains...

1M ago

OMER

Omeros Enters Securities Purchase Agreement with Polar

Omeros ( ($OMER) ) has issued an announcement. On July 24, 2025, Omeros Corporation entered into a Securities...

1M ago

OMER

Omeros to sell 5.366M shares at $4.10 in registered direct offering

Omeros (OMER) announced that it entered into a securities purchase agreement with Polar Asset Management Partners to sell...

1M ago

OMER

Omeros submission adds another 2026 catalyst, says H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes keeps a Buy rating on Omeros (OMER) with a $9 price target after...

2M ago

OMER

Omeros submits narsoplimab marketing authorization application to the EMA

Omeros (OMER) announced the recent submission of a marketing authorization application to the European Medicines Agency for narsoplimab...

2M ago

OMER

OMER FAQ

What was Omeros Corp’s price range in the past 12 months?

Omeros Corp lowest stock price was $2.95 and its highest was $13.60 in the past 12 months.

What is Omeros Corp’s market cap?

Omeros Corp’s market cap is $284.47M.

When is Omeros Corp’s upcoming earnings report date?

Omeros Corp’s upcoming earnings report date is Nov 05, 2025 which is in 60 days.

How were Omeros Corp’s earnings last quarter?

Omeros Corp released its earnings results on Aug 14, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.503 by $0.073.

Is Omeros Corp overvalued?

According to Wall Street analysts Omeros Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Omeros Corp pay dividends?

Omeros Corp does not currently pay dividends.

What is Omeros Corp’s EPS estimate?

Omeros Corp’s EPS estimate is -0.45.

How many shares outstanding does Omeros Corp have?

Omeros Corp has 68,055,824 shares outstanding.

What happened to Omeros Corp’s price movement after its last earnings report?

Omeros Corp reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.503. Following the earnings report the stock price went up 7.039%.

Which hedge fund is a major shareholder of Omeros Corp?

Currently, no hedge funds are holding shares in OMER

Omeros Stock Smart Score

Neutral

Fundamentals

Return on Equity

87.26%

Trailing 12-Months

Asset Growth

-43.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Omeros Corp

Omeros Corporation (OMER) is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical conditions. The company operates primarily in the field of inflammation, coagulopathies, and central nervous system disorders. Omeros' lead product, Omidria, is used in cataract and lens replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain. Additionally, the company is engaged in multiple clinical-stage development programs targeting conditions such as complement-mediated diseases and addiction.

Omeros (OMER) Earnings & Revenues

Historic Earnings Reports

OMER Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call conveyed a mostly positive outlook, with significant progress in financial restructuring and regulatory advancements for narsoplimab, despite some delays and decreased income from certain operations.View all OMER earnings summaries

OMER Stock 12 Month Forecast

Average Price Target

$9.00

▲(115.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","3.75":"$3.75","6.5":"$6.5","9.25":"$9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.6523076923076925,5.014615384615385,5.376923076923077,5.739230769230769,6.101538461538462,6.463846153846154,6.826153846153846,7.188461538461539,7.550769230769231,7.913076923076924,8.275384615384615,8.637692307692308,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.6523076923076925,5.014615384615385,5.376923076923077,5.739230769230769,6.101538461538462,6.463846153846154,6.826153846153846,7.188461538461539,7.550769230769231,7.913076923076924,8.275384615384615,8.637692307692308,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.6523076923076925,5.014615384615385,5.376923076923077,5.739230769230769,6.101538461538462,6.463846153846154,6.826153846153846,7.188461538461539,7.550769230769231,7.913076923076924,8.275384615384615,8.637692307692308,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.36,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.02,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >